FORM 4

obligations may continue. See

Instruction 1(b)

Check this box if no longer subject to Section 16. Form 4 or Form 5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Lengauer Christoph					2. Issuer Name and Ticker or Trading Symbol Blueprint Medicines Corp [BPMC]									Check	all applicable) Director		g Person(s) to Issuer 10% Owner Other (specify	
(Last) (First) (Middle) C/O BLUEPRINT MEDICINES CORPORATION 38 SIDNEY STREET, SUITE 200				3. Date of Earliest Transaction (Month/Day/Year) 12/15/2015									X	below) below) Chief Scientific Officer			w)	
				4. If	Line) X Form filed						filed by One Reporting Person filed by More than One Reporting							
	Tabl	e I - No	n-Deriv	ative	Sec	uritie	s Ac	quired	, Dis	sposed o	f, or	Ben	efici	ally (Dwne	ed		
Date				Execution Date,								and 5) Sec Ben Owr		ities icially d Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	of Indirect		
								Code	v	Amount	(A) (D)	or	Price		Trans	action(s)		(1130.4)
Common Stock 12			12/15/	2015	015			S ⁽¹⁾		500]	o	\$25		102,834		D	
Common Stock 12			12/16/	2015	.015			S ⁽¹⁾		24,156])	\$25.03(2)		78,678		D	
Common Stock 12/17			2015				S ⁽¹⁾		6,463 D) ·	\$ <mark>25.</mark> .	.14 ⁽³⁾		2,215	D		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
Derivative Conversion Date Execution Security or Exercise (Month/Day/Year) if any		on Date,	4. Transaction Code (Instr. 8)		Securities Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Expiration Dat (Month/Day/Ye		te ear) Expiration	Amor Or Nur of		ount mber		ative rity	derivative Securities Beneficially Owned Following Reported	Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership (Instr. 4)	
	(Fi JEPRINT M EY STREE IDGE M (St Stock Stock Stock Stock	(First) (JEPRINT MEDICINES CO EY STREET, SUITE 200 IDGE MA (State) (Table Security (Instr. 3) Stock Stock Stock Stock 2. Conversion or Exercise Price of Derivative (Month/Day/Year)	(First) (Middle) JEPRINT MEDICINES CORPORA EY STREET, SUITE 200 IDGE MA 02139 (State) (Zip) Table I - No Security (Instr. 3) Stock Stock Stock Table II - Conversion or Exercise Price of Derivative I Stock (Month/Day/Year) Stock (Month/Day/Year) 3A. Deer Execution if any (Month/IIII)	(First) (Middle) JEPRINT MEDICINES CORPORATION EY STREET, SUITE 200 IDGE MA 02139 (State) (Zip) Table I - Non-Deriv Security (Instr. 3) 2. Transa Date (Month/D Stock 12/15/ Stock 12/17/ Table II - Derivat (e.g., p) 2. Table II - Derivat (e.g., p) 2. Conversion or Exercise Price of Derivative (Month/Day/Year)	(First) (Middle) JEPRINT MEDICINES CORPORATION EY STREET, SUITE 200 Table I - Non-Derivative Security (Instr. 3) Stock 12/15/2015 Stock 12/17/2015 Table II - Derivative S (e.g., puts, comported on the purishing of the	Conversion or Exercise Price of Derivative Security (Month/Day/Year) Security (Mon	Stock 12/15/2015 Stock 12/16/2015 Stock 12/17/2015 Stock	Blueprint Medic	Blueprint Medicines Control	Blueprint Medicines Corporation Corporation	Blueprint Medicines Corp BPMC	Blueprint Medicines Corp BPMC	Blueprint Medicines Corp BPMC	Blueprint Medicines Corp [BPMC] (Instrict of the content of the content of the corp	Blueprint Medicines Corp BPMC Check	Blueprint Medicines Corp BPMC Check all applied Check al	Blueprint Medicines Corp BPMC Cheek all applicable Director X Officer (give title below) Chief Scient 12/15/2015 S. Date of Earliest Transaction (Month/Day/Year) Chief Scient 12/15/2015 Chief Scient 12/15/2015 Chief Scient Chief Sc	Blueprint Medicines Corp BPMC Check all applicable) Check Director 10% Other below) Error Chief Scientific Office Chief Scient

Explanation of Responses:

- 1. The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- 2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$25.00 to \$25.09 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- 3. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$25.00 to \$25.60 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

/s/ Christine Bellon, Attorneyin-Fact

12/17/2015

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.